Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Y. Xia, Z. Y. Xu-Monette, A. Tzankov, X. Li, G. C. Manyam, V. Murty, G. Bhagat, Shanxiang Zhang, L. Pasqualucci, C. Visco, K. Dybkaer, A. Chiu, A. Orazi, Y. Zu, K. L. Richards, E. D. Hsi, W. W.L. Choi, J. H. Van Krieken, J. Huh, M. PonzoniA. J.M. Ferreri, M. B. Møller, B. M. Parsons, J. N. Winter, M. A. Piris, J. Westin, N. Fowler, R. N. Miranda, C. Y. Ok, Y. Li, J. Li, L. J. Medeiros, K. H. Young

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.

Original languageEnglish (US)
Pages (from-to)625-636
Number of pages12
JournalLeukemia
Volume31
Issue number3
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Sequence Deletion
Plasma Cells
Cell Differentiation
Germinal Center
Gene Expression Profiling
Exons
Neoplasms
Proteins
Up-Regulation
Cell Proliferation
Phenotype

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Xia, Y., Xu-Monette, Z. Y., Tzankov, A., Li, X., Manyam, G. C., Murty, V., ... Young, K. H. (2017). Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia, 31(3), 625-636. https://doi.org/10.1038/leu.2016.243

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. / Xia, Y.; Xu-Monette, Z. Y.; Tzankov, A.; Li, X.; Manyam, G. C.; Murty, V.; Bhagat, G.; Zhang, Shanxiang; Pasqualucci, L.; Visco, C.; Dybkaer, K.; Chiu, A.; Orazi, A.; Zu, Y.; Richards, K. L.; Hsi, E. D.; Choi, W. W.L.; Van Krieken, J. H.; Huh, J.; Ponzoni, M.; Ferreri, A. J.M.; Møller, M. B.; Parsons, B. M.; Winter, J. N.; Piris, M. A.; Westin, J.; Fowler, N.; Miranda, R. N.; Ok, C. Y.; Li, Y.; Li, J.; Medeiros, L. J.; Young, K. H.

In: Leukemia, Vol. 31, No. 3, 01.03.2017, p. 625-636.

Research output: Contribution to journalArticle

Xia, Y, Xu-Monette, ZY, Tzankov, A, Li, X, Manyam, GC, Murty, V, Bhagat, G, Zhang, S, Pasqualucci, L, Visco, C, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Westin, J, Fowler, N, Miranda, RN, Ok, CY, Li, Y, Li, J, Medeiros, LJ & Young, KH 2017, 'Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma', Leukemia, vol. 31, no. 3, pp. 625-636. https://doi.org/10.1038/leu.2016.243
Xia, Y. ; Xu-Monette, Z. Y. ; Tzankov, A. ; Li, X. ; Manyam, G. C. ; Murty, V. ; Bhagat, G. ; Zhang, Shanxiang ; Pasqualucci, L. ; Visco, C. ; Dybkaer, K. ; Chiu, A. ; Orazi, A. ; Zu, Y. ; Richards, K. L. ; Hsi, E. D. ; Choi, W. W.L. ; Van Krieken, J. H. ; Huh, J. ; Ponzoni, M. ; Ferreri, A. J.M. ; Møller, M. B. ; Parsons, B. M. ; Winter, J. N. ; Piris, M. A. ; Westin, J. ; Fowler, N. ; Miranda, R. N. ; Ok, C. Y. ; Li, Y. ; Li, J. ; Medeiros, L. J. ; Young, K. H. / Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. In: Leukemia. 2017 ; Vol. 31, No. 3. pp. 625-636.
@article{99a07164f61a42ceb8a07042d1b3903d,
title = "Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma",
abstract = "PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63{\%} of the ABC-DLBCL patients were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.",
author = "Y. Xia and Xu-Monette, {Z. Y.} and A. Tzankov and X. Li and Manyam, {G. C.} and V. Murty and G. Bhagat and Shanxiang Zhang and L. Pasqualucci and C. Visco and K. Dybkaer and A. Chiu and A. Orazi and Y. Zu and Richards, {K. L.} and Hsi, {E. D.} and Choi, {W. W.L.} and {Van Krieken}, {J. H.} and J. Huh and M. Ponzoni and Ferreri, {A. J.M.} and M{\o}ller, {M. B.} and Parsons, {B. M.} and Winter, {J. N.} and Piris, {M. A.} and J. Westin and N. Fowler and Miranda, {R. N.} and Ok, {C. Y.} and Y. Li and J. Li and Medeiros, {L. J.} and Young, {K. H.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/leu.2016.243",
language = "English (US)",
volume = "31",
pages = "625--636",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

AU - Xia, Y.

AU - Xu-Monette, Z. Y.

AU - Tzankov, A.

AU - Li, X.

AU - Manyam, G. C.

AU - Murty, V.

AU - Bhagat, G.

AU - Zhang, Shanxiang

AU - Pasqualucci, L.

AU - Visco, C.

AU - Dybkaer, K.

AU - Chiu, A.

AU - Orazi, A.

AU - Zu, Y.

AU - Richards, K. L.

AU - Hsi, E. D.

AU - Choi, W. W.L.

AU - Van Krieken, J. H.

AU - Huh, J.

AU - Ponzoni, M.

AU - Ferreri, A. J.M.

AU - Møller, M. B.

AU - Parsons, B. M.

AU - Winter, J. N.

AU - Piris, M. A.

AU - Westin, J.

AU - Fowler, N.

AU - Miranda, R. N.

AU - Ok, C. Y.

AU - Li, Y.

AU - Li, J.

AU - Medeiros, L. J.

AU - Young, K. H.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.

AB - PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively evaluated for PRDM1/BLIMP-1 deletion, mutation, and protein expression. BLIMP-1 expression was frequently associated with the ABC phenotype and plasmablastic morphologic subtype of DLBCL, yet 63% of the ABC-DLBCL patients were negative for BLIMP-1 protein expression. In these patients, loss of BLIMP-1 was associated with Myc overexpression and decreased expression of p53 pathway molecules. In addition, homozygous PRDM1 deletions and PRDM1 mutations within exons 1 and 2, which encode for domains crucial for transcriptional repression, were found to show a poor prognostic impact in patients with ABC-DLBCL but not in those with germinal center B-cell-like DLBCL (GCB-DLBCL). Gene expression profiling revealed that loss of PRDM1/BLIMP-1 expression correlated with a decreased plasma-cell differentiation signature and upregulation of genes involved in B-cell receptor signaling and tumor-cell proliferation. In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.

UR - http://www.scopus.com/inward/record.url?scp=84989216751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989216751&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.243

DO - 10.1038/leu.2016.243

M3 - Article

C2 - 27568520

AN - SCOPUS:84989216751

VL - 31

SP - 625

EP - 636

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -